Goldman Sachs raised the firm’s price target on Olema Oncology (OLMA) to $38 from $26 and keeps a Buy rating on the shares. Roche’s (RHHBY) detailed Phase 3 lidERA results for giredestrant at the San Antonio Breast Cancer Symposium showed encouraging efficacy with a safety/tolerability profile that supports SERD monotherapy as a viable adjuvant option for ER+/HER2- breast cancer, offering positive read-through for Olema’s palazestrant and its potential to expand into the large adjuvant market, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Promising Potential of Olema Pharmaceuticals’ Palazestrant in Transforming ER+/HER2- Breast Cancer Treatment
- Positive Outlook for Olema’s OPERA-02 Trial Based on Roche’s Promising Giredestrant Data
- Buy Rating for Olema Pharmaceuticals Driven by Promising Oral SERD Potential in Breast Cancer Treatment
- Olema Oncology price target raised to $43 from $30 at Jefferies
- Olema Oncology rises 11.7%